<DOC>
	<DOC>NCT00220298</DOC>
	<brief_summary>This study will evaluate the preparation of testosterone undecanoate under conditions which resemble real-life situations.</brief_summary>
	<brief_title>Assessment of Long Term Treatment With Testosterone Undecanoate in Males With Hypogonadism</brief_title>
	<detailed_description>The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Hypogonadal men, aged 1875 years with low serum total testosterone (TT) levels and symptoms of androgen deficiency Tumors of the prostate or the male mammary gland including suspicion thereof. Past or present liver tumors or chronic hepatic disease with impairment of liver function, Severe acne.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>